Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
21 Mar 2024

Historique:

received: 29 09 2022

accepted: 13 03 2024

medline: 22 3 2024

pubmed: 22 3 2024

entrez: 22 3 2024

Statut: epublish

Résumé

Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8

Identifiants

DOI: 10.1038/s41467-024-46873-w PMID: 38514660

pubmed: 38514660

doi: 10.1038/s41467-024-46873-w

pii: 10.1038/s41467-024-46873-w

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

2528

Informations de copyright

Références

Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212–224 (2021).

pubmed: 33574607 doi: 10.1038/s41591-021-01233-9

Dersh, D., Holly, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21, 116–128 (2021).

pubmed: 32820267 doi: 10.1038/s41577-020-0390-6

Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).

pubmed: 31467405 doi: 10.1038/s41577-019-0210-z

Galluzzi, L., Humeau, J., Buque, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741 (2020).

pubmed: 32760014 doi: 10.1038/s41571-020-0413-z

Cytlak, U. M. et al. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat. Rev. Immunol. 22, 124–138 (2022).

pubmed: 34211187 doi: 10.1038/s41577-021-00568-1

Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I. & Galluzzi, L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat. Immunol. 21, 120–134 (2020).

pubmed: 31873291 doi: 10.1038/s41590-019-0561-4

Petroni, G., Buque, A., Zitvogel, L., Kroemer, G. & Galluzzi, L. Immunomodulation by targeted anticancer agents. Cancer Cell 39, 310–345 (2021).

pubmed: 33338426 doi: 10.1016/j.ccell.2020.11.009

Galluzzi, L., Zitvogel, L. & Kroemer, G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunol. Res. 4, 895–902 (2016).

pubmed: 27803050 doi: 10.1158/2326-6066.CIR-16-0197

Fridman, W. H., Zitvogel, L., Sautes-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).

pubmed: 28741618 doi: 10.1038/nrclinonc.2017.101

Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).

pubmed: 33139244 pmcid: 7710563 doi: 10.1158/2159-8290.CD-20-0522

Paijens, S. T. et al. Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. Oncoimmunology 10, 1935104 (2021).

pubmed: 34123576 pmcid: 8183551 doi: 10.1080/2162402X.2021.1935104

Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).

pubmed: 28102259 doi: 10.1038/nature21349

Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).

pubmed: 31092904 doi: 10.1038/s41568-019-0144-6

Downs-Canner, S. M., Meier, J., Vincent, B. G. & Serody, J. S. B cell function in the tumor microenvironment. Annu Rev. Immunol. 40, 169–193 (2022).

pubmed: 35044794 doi: 10.1146/annurev-immunol-101220-015603

Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).

pubmed: 34990248 doi: 10.1126/science.abf9419

Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441–457 (2022).

pubmed: 35365796 doi: 10.1038/s41571-022-00619-z

Martinet, L. et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 1, 829–839 (2012).

pubmed: 23162750 pmcid: 3489738 doi: 10.4161/onci.20492

Goc, J. et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705–715 (2014).

pubmed: 24366885 doi: 10.1158/0008-5472.CAN-13-1342

Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147–2158 (2014).

pubmed: 24523438 doi: 10.1158/1078-0432.CCR-13-2590

Lee, H. J. et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am. J. Clin. Pathol. 144, 278–288 (2015).

pubmed: 26185313 doi: 10.1309/AJCPIXUYDVZ0RZ3G

Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509–528 (2022).

pubmed: 34937915 doi: 10.1038/s41573-021-00345-8

Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).

pubmed: 31942071 doi: 10.1038/s41586-019-1914-8

Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).

pubmed: 31942075 pmcid: 8762581 doi: 10.1038/s41586-019-1922-8

Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527–541.e525 (2022).

pubmed: 35231421 doi: 10.1016/j.immuni.2022.02.001

Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).

pubmed: 31942077 doi: 10.1038/s41586-019-1906-8

Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794–802 (2021).

pubmed: 35118423 pmcid: 8809887 doi: 10.1038/s43018-021-00232-6

Nishino, M., Ramaiya, N. H., Hatabu, H. & Hodi, F. S. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).

pubmed: 28653677 pmcid: 5650537 doi: 10.1038/nrclinonc.2017.88

Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662–680 (2020).

pubmed: 32753728 doi: 10.1038/s41568-020-0285-7

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 10, eaat7807 (2018).

pubmed: 30232229 doi: 10.1126/scitranslmed.aat7807

Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).

pubmed: 29262275 pmcid: 6549688 doi: 10.1056/NEJMc1713444

Anagnostou, V., Bardelli, A., Chan, T. A. & Turajlic, S. The status of tumor mutational burden and immunotherapy. Nat. Cancer 3, 652–656 (2022).

pubmed: 35764740 doi: 10.1038/s43018-022-00382-1

Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).

pubmed: 33580222 doi: 10.1038/s41571-021-00473-5

Fucikova, J. et al. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J. Immunother. Cancer 9, e002873 (2021).

pubmed: 34645669 pmcid: 8515436 doi: 10.1136/jitc-2021-002873

Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640–656 (2022).

Demuytere, J., Ernst, S., van Ovost, J., Cosyns, S. & Ceelen, W. The tumor immune microenvironment in peritoneal carcinomatosis. Int. Rev. Cell Mol. Biol. 371, 63–95 (2022).

pubmed: 35965001 doi: 10.1016/bs.ircmb.2022.04.015

Rathod, S. T cells in the peritoneum. Int. Rev. Cell Mol. Biol. 371, 15–41 (2022).

pubmed: 35964999 doi: 10.1016/bs.ircmb.2022.04.013

Chaurio, R. A. et al. TGF-beta-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity 55, 115–128.e119 (2022).

pubmed: 35021053 pmcid: 8852221 doi: 10.1016/j.immuni.2021.12.007

Nielsen, J. S. et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012).

pubmed: 22553348 doi: 10.1158/1078-0432.CCR-12-0234

Montfort, A. et al. A Strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017).

pubmed: 27354470 doi: 10.1158/1078-0432.CCR-16-0081

Kroeger, D. R., Milne, K. & Nelson, B. H. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016).

pubmed: 26763251 doi: 10.1158/1078-0432.CCR-15-2762

Biswas, S. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464–470 (2021).

pubmed: 33536615 pmcid: 7969354 doi: 10.1038/s41586-020-03144-0

Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208–1222.e1221 (2022).

pubmed: 35305314 doi: 10.1016/j.cell.2022.02.012

Lynch, K. T. et al. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. J. Immunother. Cancer 9, e002273 (2021).

pubmed: 34103353 pmcid: 8190052 doi: 10.1136/jitc-2020-002273

Silina, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308–1320 (2018).

pubmed: 29279354 doi: 10.1158/0008-5472.CAN-17-1987

Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7, e1378844 (2018).

pubmed: 29416939 doi: 10.1080/2162402X.2017.1378844

Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 16, 64 (2015).

pubmed: 25853550 pmcid: 4377852 doi: 10.1186/s13059-015-0620-6

Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).

pubmed: 27765066 pmcid: 5073889 doi: 10.1186/s13059-016-1070-5

Coppola, D. et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011).

pubmed: 21703392 pmcid: 3123872 doi: 10.1016/j.ajpath.2011.03.007

Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).

pubmed: 23097687 pmcid: 3479449 doi: 10.1038/srep00765

Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545–557.e513 (2022).

pubmed: 35427494 pmcid: 9096229 doi: 10.1016/j.ccell.2022.03.008

Fucikova, J. et al. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clin. Cancer Res. 25, 4820–4831 (2019).

pubmed: 31076549 doi: 10.1158/1078-0432.CCR-18-4175

Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).

pubmed: 30778252 pmcid: 6673650 doi: 10.1038/s41590-019-0312-6

Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50, 195–211.e110 (2019).

pubmed: 30635237 doi: 10.1016/j.immuni.2018.12.021

Wang, D. et al. A comprehensive profile of TCF1(+) progenitor and TCF1(-) terminally exhausted PD-1(+)CD8(+) T cells in head and neck squamous cell carcinoma: implications for prognosis and immunotherapy. Int. J. Oral. Sci. 14, 8 (2022).

pubmed: 35153298 pmcid: 8841504 doi: 10.1038/s41368-022-00160-w

Connolly, K. A. et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci. Immunol. 6, eabg7836 (2021).

pubmed: 34597124 pmcid: 8593910 doi: 10.1126/sciimmunol.abg7836

Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191–1206.e1121 (2019).

pubmed: 31730857 pmcid: 6911685 doi: 10.1016/j.cell.2019.10.028

King, H. W. et al. Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics. Sci. Immunol. 6, eabe6291 (2021).

pubmed: 33579751 doi: 10.1126/sciimmunol.abe6291

Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).

pubmed: 30395155 doi: 10.1093/annonc/mdy495

Beach, J. A. et al. Sphingosine kinase 1 is required for TGF-beta mediated fibroblastto- myofibroblast differentiation in ovarian cancer. Oncotarget 7, 4167–4182 (2016).

pubmed: 26716409 doi: 10.18632/oncotarget.6703

Lauss, M., Donia, M., Svane, I. M. & Jonsson, G. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy? Clin. Cancer Res. 28, 1751–1758 (2022).

pubmed: 34965949 doi: 10.1158/1078-0432.CCR-21-1130

Iglesia, M. D. et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin. Cancer Res. 20, 3818–3829 (2014).

pubmed: 24916698 pmcid: 4102637 doi: 10.1158/1078-0432.CCR-13-3368

Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289–300.e284 (2022).

pubmed: 35216676 doi: 10.1016/j.ccell.2022.02.002

Ruffin, A. T. et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat. Commun. 12, 3349 (2021).

pubmed: 34099645 pmcid: 8184766 doi: 10.1038/s41467-021-23355-x

Martinet, L. et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71, 5678–5687 (2011).

pubmed: 21846823 doi: 10.1158/0008-5472.CAN-11-0431

Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621 868–876 (2023).

Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).

pubmed: 29634943 pmcid: 7116508 doi: 10.1016/j.ccell.2018.03.012

Blank, C. U. et al. Defining ‘T cell exhaustion. Nat. Rev. Immunol. 19, 665–674 (2019).

pubmed: 31570879 pmcid: 7286441 doi: 10.1038/s41577-019-0221-9

Garaud, S., Dieu-Nosjean, M. C. & Willard-Gallo, K. T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nat. Commun. 13, 2259 (2022).

pubmed: 35473931 pmcid: 9043192 doi: 10.1038/s41467-022-29753-z

Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275–1289 (2021).

pubmed: 34363762 doi: 10.1016/S1470-2045(21)00342-9

Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J. Clin. Oncol. 39, JCO2100306 (2021).

Hladikova, K. et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J. Immunother. Cancer 7, 261 (2019).

pubmed: 31623665 pmcid: 6796441 doi: 10.1186/s40425-019-0726-6

Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135 (2018).

pubmed: 30049748 doi: 10.1158/1078-0432.CCR-18-1481

Wennhold, K. et al. CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol. Res. 9, 1098–1108 (2021).

pubmed: 34155067 doi: 10.1158/2326-6066.CIR-20-0949

O’Sullivan, B. et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 18, 849–851 (2017).

pubmed: 28677562 pmcid: 5851445 doi: 10.1016/S1470-2045(17)30438-2

Glass, G., Papin, J. A. & Mandell, J. W. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J. Histochem. Cytochem. 57, 899–905 (2009).

pubmed: 19365090 pmcid: 2746723 doi: 10.1369/jhc.2009.953612

Keane, T. M. et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289–294 (2011).

pubmed: 21921910 pmcid: 3276836 doi: 10.1038/nature10413

Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

pubmed: 23104886 doi: 10.1093/bioinformatics/bts635

Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591–594 (2018).

pubmed: 30013048 doi: 10.1038/s41592-018-0051-x

Hensler, M. et al. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J. Immunother. Cancer 8, e000979 (2020).

pubmed: 32819974 pmcid: 7443306 doi: 10.1136/jitc-2020-000979